+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Differential effects of scopolamine on in vivo binding of dopamine transporter and vesicular monoamine transporter radioligands in rat brain



Differential effects of scopolamine on in vivo binding of dopamine transporter and vesicular monoamine transporter radioligands in rat brain



Experimental Neurology 188(2): 387-390



The in vivo equilibrium specific binding of d-threo-[3H]methylphenidate, a radioligand for the dopamine transporter (DAT), and +-alpha-[3H]dihydrotetrabenazine, a radioligand for the vesicular monoamine transporter (VMAT2), were examined in rat brain with and without prior administration of 5 mg/kg scopolamine. Drug-treated animals exhibited a 30% increase in d-threo-[3H]methylphenidate binding to the DAT in the striatum relative to controls. No changes in specific binding of +-alpha-[3H]dihydrotetrabenazine were observed in any brain region following scopolamine pretreatment. Cholinergic drugs thus differentially affect in vivo specific binding of DAT and VMAT2 radioligands, suggesting this should be a consideration in selection of in vivo markers for imaging studies of dopaminergic terminals in the brain of animals and humans.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011956857

Download citation: RISBibTeXText

PMID: 15246838

DOI: 10.1016/j.expneurol.2004.05.001


Related references

Rapid and differential losses of in vivo dopamine transporter and vesicular monoamine transporter radioligand binding in MPTP-treated mice. Synapse (New York) 35(4): 250-255, March 15, 2000

Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice. Synapse 35(4): 250-255, 2000

No differential regulation of dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) binding in a primate model of Parkinson disease. Plos One 7(2): E31439, 2012

Dopamine D1, D2, D3 receptors, vesicular monoamine transporter type-2 (VMAT2) and dopamine transporter (DAT) densities in aged human brain. Plos One 7(11): E49483, 2013

Age-related decreases in striatal dopamine transporter and vesicular monoamine transporter binding sites in alcoholics. Alcoholism Clinical & Experimental Research 22(3 ABSTR SUPPL ): 48A, 1998

Increased Vesicular Monoamine Transporter 2 (VMAT2) and Dopamine Transporter (DAT) Expression in Adolescent Brain Development: A Longitudinal Micro-PET/CT Study in Rodent. Frontiers in Neuroscience 12: 1052-1052, 2019

Aging effects on locomotor activity in dopamine transporter and vesicular monoamine transporter knockout mice. Society for Neuroscience Abstracts 26(1-2): Abstract No -344 5, 2000

Differential effects of dopamine reuptake inhibitors and releasers on the vesicular monoamine transporter 2. Society for Neuroscience Abstract Viewer & Itinerary Planner : Abstract No 807 4, 2002

Increased dopamine D2High receptors in knockouts of the dopamine transporter and the vesicular monoamine transporter may contribute to spontaneous hyperactivity and dopamine supersensitivity. Synapse 61(7): 573-576, 2007

Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter. Molecular Pharmacology 47(2): 368-373, 1995

Vesicular monoamine transporter 2 and dopamine transporter are molecular targets of Pitx3 in the ventral midbrain dopamine neurons. Journal of Neurochemistry 111(5): 1202-1212, 2009

In vivo binding of -alpha- dihydrotetrabenazine to the vesicular monoamine transporter of rat brain Bolus vs equilibrium studies. European Journal of Pharmacology 331(2-3): 161-168, 1997

Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Annals of Neurology 40(3): 428-439, 1996

Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles. Biochemical Pharmacology 38(15): 2395-2404, 1989

The expression of vesicular glutamate transporter 3 and vesicular monoamine transporter 2 induced by brain-derived neurotrophic factor in dorsal root ganglion neurons in vitro. Brain Research Bulletin 100: 93-106, 2014